title: Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome.
abstract: BACKGROUND
  This study was designed to determine the debated prognostic significance of reverse transcriptase-polymerase chain reaction (RT-PCR) positivity in melanoma patients' sentinel lymph node (SLN) negative by conventional histopathology (PATH).
  
  
  METHODS
  Patients with primary stage I-II cutaneous melanoma underwent radioguided sentinel lymphadenectomy. Their SLNs were assessed for tyrosinase (Tyr) and melanoma antigens recognized by T-cells (MART-1) mRNA expression using RT-PCR, in parallel with hematoxylin and eosin staining and immunohistochemistry. Tyr and MART-1 expression in the SLNs were correlated with PATH assay results, standard prognostic factors, time to progression and overall survival.
  
  
  RESULTS
  Twenty-three of the 124 patients (18.5%) had positive SLNs by both PATH and RT-PCR (PATH+/PCR+). Sixteen patients (13%) were negative by PATH and positive by RT-PCR (PATH-/PCR+). Eighty-five patients (68.5%) had SLNs that were negative by both PATH and RT-PCR (PATH-/PCR-). At a median follow-up of 30 months, recurrence rates among the three cohorts were statistically different (PATH+/PCR+, 60%; PATH-/PCR+, 31%; PATH-/PCR-, 9.4%). Seven of 23 (30%) and two of 16 (12.5%) patients died in the PATH+/PCR+ and PATH-/PCR+ SLN groups, respectively, whereas no patient died in the PATH-/PCR- SLN group.
  
  
  CONCLUSIONS
  RT-PCR is more sensitive than PATH to detect SLN metastases and it is a reliable predictor of disease relapse in stage I-II melanoma patients.
authors.affiliation: Division of Medical Oncology and Plastic Surgery, University Hospital, Pisa. a.romanini@ao-pisa.toscana.it
authors.forename: A
authors.initials: A
authors.lastname: Romanini
authors.forename: G
authors.initials: G
authors.lastname: Manca
authors.forename: D
authors.initials: D
authors.lastname: Pellegrino
authors.forename: R
authors.initials: R
authors.lastname: Murr
authors.forename: S
authors.initials: S
authors.lastname: Sarti
authors.forename: F
authors.initials: F
authors.lastname: Bianchi
authors.forename: A
authors.initials: A
authors.lastname: Alsharif
authors.forename: C
authors.initials: C
authors.lastname: Orlandini
authors.forename: V
authors.initials: V
authors.lastname: Zucchi
authors.forename: M
authors.initials: M
authors.lastname: Castagna
authors.forename: D
authors.initials: D
authors.lastname: Gandini
authors.forename: G
authors.initials: G
authors.lastname: Salimbeni
authors.forename: F
authors.initials: F
authors.lastname: Ghiara
authors.forename: P
authors.initials: P
authors.lastname: Barachini
authors.forename: G
authors.initials: G
authors.lastname: Mariani
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D006801:Humans; D008197:Lymph Node Excision; D058965:MART-1 Antigen; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D008875:Middle Aged; D014442:Monophenol Monooxygenase / Q000235:genetics*; D009363:Neoplasm Proteins / Q000235:genetics*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000951:Antigens, Neoplasm; D058965:MART-1 Antigen; C548667:MLANA protein, human; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D014442:Monophenol Monooxygenase